# BPC-157 + TB-500 (Capsule)

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/bpc-157-tb-500-capsule (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: The Wolverine Stack in oral capsule form for convenient systemic recovery support.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/bpc-157-tb-500-capsule

### BPC-157 + TB-500 Oral Capsule The Wolverine Stack in oral capsule form for convenient systemic recovery support. \*\*Blends & Combos · Limited Evidence · Research Only\*\* ### Description This oral capsule combines BPC-157 and TB-500 — the two most widely researched recovery peptides — in a convenient oral format for systemic recovery support. BPC-157 (Body Protection Compound 157) is a 15-amino acid peptide derived from human gastric juice, while TB-500 is a synthetic fragment of Thymosin Beta-4, an actin-regulating protein found in virtually all human cells. While injectable forms of both peptides are preferred for acute musculoskeletal injuries due to higher bioavailability, oral capsules provide meaningful GI healing plus systemic absorption that supports general recovery, inflammation reduction, and tissue repair. This combination is particularly valued for individuals seeking convenient daily recovery support without injections, or as a maintenance protocol following an injectable loading phase. The complementary mechanisms of these two peptides — BPC-157 targeting angiogenesis and growth factor signaling, TB-500 targeting actin dynamics and cell migration — make them highly synergistic. ### Key Characteristics - \*\*Molecular Weight:\*\* Not specified - \*\*Half-Life:\*\* Varies - \*\*Administration Routes:\*\* Oral capsule - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Daily - \*\*Cycle Length:\*\* 6–8 weeks ### Investigated Benefits - GI healing - Anti-inflammatory effects - Systemic recovery support - Convenient oral administration \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action BPC-157 in oral form acts locally on the GI mucosa through FAK-paxillin pathway activation and VEGF upregulation, while achieving partial systemic absorption that provides anti-inflammatory and healing effects throughout the body. TB-500 (Thymosin Beta-4 fragment) sequesters G-actin to regulate actin polymerization dynamics, which is essential for cell migration, wound healing, and tissue repair. TB-500 also upregulates matrix metalloproteinases (MMPs) that facilitate tissue remodeling and promotes angiogenesis through VEGF and laminin-5 signaling. Together, BPC-157 and TB-500 address healing from complementary angles: BPC-157 primarily drives angiogenesis and growth factor signaling, while TB-500 primarily drives cell migration and actin-mediated tissue reconstruction. This dual mechanism provides broader and more comprehensive recovery support than either compound alone. ### Dosing & Protocol - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Daily - \*\*Cycle Length:\*\* 6–8 weeks - \*\*Administration:\*\* Oral capsule \*\*Protocol Notes:\*\* Take on empty stomach. For musculoskeletal injuries, injectable forms are preferred. Oral form is convenient for GI and general systemic support. ### Storage Information Store at room temperature, away from light and moisture. ### Quality & Sourcing Standards When sourcing BPC-157 + TB-500 (Capsule) for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Both components have extensive preclinical evidence 2. Oral BPC-157 effective for GI conditions 3. Combination provides complementary healing mechanisms ### Evidence Level \*\*Limited Evidence\*\* — Primarily animal studies with limited human data. Mechanism is plausible but clinical efficacy is unconfirmed. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.